Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Marbach

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Cell Reports Methods|September 16, 2025
Comparison of single-cell RNA-seq methods to enable transcriptome profiling of neutrophils in clinical samplesKlas Hatje, Kim Schneider, Sabrina Danilin, et al.
Life Science Alliance|May 17, 2022
DUSP4 protects BRAF- and NRAS-mutant melanoma from oncogene overdose through modulation of MITFNuria Gutierrez-Prat, Hedwig L Zuberer, Luca Mangano, et al.
Journal of Visualized Experiments : Jove|May 4, 2026
Detecting Inter-Individual Contamination and Mismatches in Multiomics Next-Generation Sequencing DataZachary Whitfield, Przemyslaw Kiljan, Monika Krzyzanowska, et al.
BMC Cancer|March 19, 2025
Immune modulation in solid tumors: a phase 1b study of RO6870810 (BET inhibitor) and atezolizumab (PD-L1 inhibitor)Daniel Marbach, Jurriaan Brouer-Visser, Laura Brennan, et al.
Nature Methods|September 1, 2019
Assessment of network module identification across complex diseasesSarvenaz Choobdar, Mehmet E Ahsen, Jake Crawford, et al.
Journal for Immunotherapy of Cancer|November 1, 2022
Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumorsMarina Natoli, Klas Hatje, Pratiksha Gulati, et al.
Nature Biotechnology|September 10, 2011
Verification of systems biology research in the age of collaborative competitionPablo Meyer, Leonidas G Alexopoulos, Thomas Bonk, et al.
Cancer Immunology Research|November 16, 2021
BET Inhibition Enhances TNF-Mediated Antitumor ImmunityLisa C Wellinger, Simon J Hogg, Dane M Newman, et al.
Nature Medicine|September 24, 2025
Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trialGeorgina V Long, Nitya Nair, Daniel Marbach, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2024
Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal CancerHans Prenen, Sanjeev Deva, Bhumsuk Keam, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Cell Reports Methods|September 16, 2025
Comparison of single-cell RNA-seq methods to enable transcriptome profiling of neutrophils in clinical samplesKlas Hatje, Kim Schneider, Sabrina Danilin, et al.
Life Science Alliance|May 17, 2022
DUSP4 protects BRAF- and NRAS-mutant melanoma from oncogene overdose through modulation of MITFNuria Gutierrez-Prat, Hedwig L Zuberer, Luca Mangano, et al.
Journal of Visualized Experiments : Jove|May 4, 2026
Detecting Inter-Individual Contamination and Mismatches in Multiomics Next-Generation Sequencing DataZachary Whitfield, Przemyslaw Kiljan, Monika Krzyzanowska, et al.
BMC Cancer|March 19, 2025
Immune modulation in solid tumors: a phase 1b study of RO6870810 (BET inhibitor) and atezolizumab (PD-L1 inhibitor)Daniel Marbach, Jurriaan Brouer-Visser, Laura Brennan, et al.
Nature Methods|September 1, 2019
Assessment of network module identification across complex diseasesSarvenaz Choobdar, Mehmet E Ahsen, Jake Crawford, et al.
Journal for Immunotherapy of Cancer|November 1, 2022
Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumorsMarina Natoli, Klas Hatje, Pratiksha Gulati, et al.
Nature Biotechnology|September 10, 2011
Verification of systems biology research in the age of collaborative competitionPablo Meyer, Leonidas G Alexopoulos, Thomas Bonk, et al.
Cancer Immunology Research|November 16, 2021
BET Inhibition Enhances TNF-Mediated Antitumor ImmunityLisa C Wellinger, Simon J Hogg, Dane M Newman, et al.
Nature Medicine|September 24, 2025
Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trialGeorgina V Long, Nitya Nair, Daniel Marbach, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2024
Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal CancerHans Prenen, Sanjeev Deva, Bhumsuk Keam, et al.
Pageof 4